French pharmaceutical company Biosantech recently will soon unveil the latest results from its Phase II clinical study of a vaccine for HIV.
The study, which took place in France, tested a TAT OYI Vaccine candidate, which is a novel vaccine that may be able to provoke a cross-protective immunity and replication of multiple subtypes of HIV.
An estimated 35 million people around the world have HIV. According to experts, just 37 of those people can access current treatments. Even though antiretroviral tritherapy ART was marginally successfully in the 1990s, scientists are still searching for ways to improve the quality of life for HIV and AIDS patients.
Dr. Donatien Mavougou will represent Biosantech in his presentation titled “IMMUNOREXTM as a vaccine approach by its ability to inhibit HIV-1 and co-infecting pathogens: the role of its lipid carrier" before the new conference, which will discuss Mavougou’s collaboration with Biosantech.
The presentation about the study results will take place Monday from 1:25-1:50 p.m at the Hilton Hotel Chicago’s DoubleTree Hotel, 9599 Skokie Blvd. in Skokie. Conference attendees will include other representatives from Biosantech, including CEO Corinne Treger, virologist Dr. Jean de Mareuil, Dr. Sonia Escaich, and IIDSRSI Institute of France Director Michel Correa.